ClinicalTrials.gg
CompletedNCT06353945Updated Nov 18, 2024

Perceived Effectiveness of the Vaginal Moisturizer Investigational Product Under Normal Conditions of Use.

An interventional study of vaginal moisturizer in Vaginal Atrophy, sponsored by Herbarium Laboratorio Botanico Ltda. Completed at 1 site in Brazil. Open to female participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-18.

Sponsored by Herbarium Laboratorio Botanico Ltda · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
25 Years to 70 Years
Sex
Female
01

Study summary

The present research project aims to evaluate the perceived effectiveness of the product under investigation under normal conditions of use for 28 days, to defend the claims "High hydration power, relief of discomfort and improvement of vaginal tone."

Read the detailed description

This research project aims to evaluate the perceived efficacy of the product under investigation under normal conditions of use for 28 days, to defend the attributes expected for this product category. The study will be carried out through the application of questionnaires, which will be answered by the participants. The study will be conducted with a Brazilian sample in which 45 research participants will be included.

02

Conditions studied

  • Vaginal Atrophy
03

In context

Lead sponsor

Herbarium Laboratorio Botanico Ltda is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range between 25 and 70 years old.
  2. Phototypes: I to IV, according to Fitzpatrick classification;
  3. Sex: female
  4. Intact skin in the evaluation region.
  5. Participants complaining of vaginal dryness;
  6. Agree to adhere to the study procedures and requirements: study time, return(s) to the laboratory to perform study procedures, home use of the product, filling out the usage diary, not changing cosmetic habits during the study period .
  7. Agree not to carry out dermatological or aesthetic treatments until the end of the study and agree not to use any products from the same category as the investigational product.
  8. Signing of the Free and Form (TCLE).

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Skin marks in the experimental area that interfere with the assessment of possible skin reactions.
  3. Active dermatoses (local or disseminated) that could interfere with the study results.
  4. History of ineffectiveness, allergic reactions, irritation or intense sensation of discomfort to topical products: health products or medications.
  5. Expected vaccination during the study or up to 3 weeks before the study;
  6. Not taking vitamin A (acid and/or its derivatives orally or topically up to 1 month before the start of the study.)
  7. Patients with immunodeficiencies.
  8. History of atopy (atopic dermatitis, allergic rhinitis, allergic bronchitis, allergic conjunctivitis, etc.).
  9. Use of non-steroidal anti-inflammatory drugs, , antihistamines, photosensitizers or up to 2 weeks before the study (or considering depot corticosteroids, the interval should be 1 month before the selection).
  10. Aesthetic or dermatological treatment up to 4 weeks before the study.
  11. Hormonal treatments not stable in the last 3 months.
  12. Hyperpigmentation associated with the use of drugs such as tetracyclines, phenothiazides or amiodarone.
  13. Hyperpigmentation associated with photosensitivity.
  14. People directly involved in carrying out this study and their families.
  15. History of lack of adherence or unwillingness to adhere to the study protocol.
  16. Any condition that, in the researcher's opinion, could compromise the study.
  17. Be participating in another study in the same region of application.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    vaginal moisturizer

    45 participants treated with vaginal moisturizer

    Device: vaginal moisturizer

Interventions

  • Devicevaginal moisturizer

    vaginal moisturizer

06

What researchers measure

Primary outcomes

  1. evaluate the perceived effectiveness of the investigational product

    The perceived efficacy of the subjective method will be evaluated by means of questionnaires answered by the research participants after the first use and 28 days of use of the investigational product using a rating scale. The results of this evaluation will be used to analyze the frequency of scores for each attribute evaluated. Based on the results of the evaluation of the product's efficacy, an analysis of the frequency of scores for each question evaluated.

    Time frame: 28 days

07

Study locations

1 site
  • Kosmoscience Ciência e Tecnologia Cosmética Ltda
    Campinas, São Paulo 13041-315, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06353945
Lead sponsor
Herbarium Laboratorio Botanico Ltda
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Jun 10, 2024
Primary completion
Jul 10, 2024
Completion
Jul 18, 2024
Last update
Nov 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion